Scandinavian ChemoTech Q2 2025: Approaching breakeven at a triple-digit growth rate
12 augusti, 08:51
12 augusti, 08:51
Redeye provides an initial take on the Q2 2025 report from Scandinavian ChemoTech. Net sales were SEK3.85m (1.68), up an exceptional 128% y/y. EBIT reached SEK-0.7m (-3.76), showing that the company is close to reaching breakeven. Despite a c200% increase in the share price from the April lows, we maintain our positive view of the company, building on the rapidly growing recurring revenue, high gross margins, and solid cost control. We expect to slightly increase our fair value range on the back of the report.
12 augusti, 08:51
Redeye provides an initial take on the Q2 2025 report from Scandinavian ChemoTech. Net sales were SEK3.85m (1.68), up an exceptional 128% y/y. EBIT reached SEK-0.7m (-3.76), showing that the company is close to reaching breakeven. Despite a c200% increase in the share price from the April lows, we maintain our positive view of the company, building on the rapidly growing recurring revenue, high gross margins, and solid cost control. We expect to slightly increase our fair value range on the back of the report.
Börsen
Aktieanalyser
Rapporter
Kryptovalutor
Inflation
Wingefors försäljning
Börsen
Aktieanalyser
Rapporter
Kryptovalutor
Inflation
Wingefors försäljning
1 DAG %
Senast
OMX Stockholm 30
1 DAG %
Senast
2 632,92